6533b839fe1ef96bd12a5ca3

RESEARCH PRODUCT

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis

Ilvars SilinsElisabeth ÅVall LundqvistBo FrankendalUldis VikmanisZhaohui WangJohn T. SchillerMartin SappJoakim Dillner

subject

Cervical cancerHpv typesPapillomavirus InfectionsAbsolute risk reductionUterine Cervical Neoplasmsvirus diseasesOdds ratioBiologyAntibodies Viralmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsConfidence intervalPathogenesisTumor Virus InfectionsCervical carcinogenesisSeroepidemiologic StudiesCase-Control StudiesVirologyGenotypemedicineHumansFemalePapillomaviridae

description

Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2·39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1·0). The relative excess risk due to interaction between HPV-6 and -16 was −2·35 (95% confidence interval, −0·04 to −4·65), indicating significant antagonism. The results suggest that infection with HPV-6 may interfere with HPV-16-associated cervical carcinogenesis.

yearjournalcountryeditionlanguage
1999-12-02Journal of General Virology
https://doi.org/10.1099/0022-1317-80-11-2931